BeOne Medicines's EBIT per Share for the
three
months ended in Mar. 2026 was $2.52.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $6.57.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for BeOne Medicines's EBIT per Share or its related term are showing as below:
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of BeOne Medicines was 29.70% per year. The lowest was -231.00% per year. And the median was -61.90% per year.
ONC's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.55 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
BeOne Medicines's EBIT for the
three
months ended in Mar. 2026 was $292 Mil.
BeOne Medicines (NAS:ONC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
BeOne Medicines EBIT per Share Related Terms
BeOne Medicines EBIT per Share Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (ONC) has a EBIT per Share of $6.57 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #999999 out of 1178 companies in the Biotechnology industry.
Is BeOne Medicines' EBIT per Share too high?
BeOne Medicines' current EBIT per Share is $6.57. The Biotechnology industry median EBIT per Share is 15.55. BeOne Medicines' value of $6.57 is 57.7% below this industry median. Based on the distribution chart, BeOne Medicines ranks #999999 out of 1178 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeOne Medicines has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' EBIT per Share compare to MRNA and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #999999 out of 1178 companies for EBIT per Share. This places BeOne Medicines in the lower half of its industry. The industry median EBIT per Share is 15.55. BeOne Medicines' value of $6.57 is 57.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current EBIT per Share of $6.57 is 57.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current EBIT per Share is $6.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $367.20, compared to a current price of $297.65 — trading 18.9% below its estimated fair value. The current EBIT per Share is $6.57 and 57.7% below the Biotechnology industry median of 15.55. BeOne Medicines' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For BeOne Medicines (ONC), the current EBIT per Share is $6.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $297.65 is trading 18.9% below its estimated GF Value™ of $367.20.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
EBIT per Share: $6.57
GF Value™: $367.20 vs. price of $297.65 (18.9% below fair value)
Industry Position: 57.7% below the Biotechnology median (#999999 of 1178)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
78GF Score
Get the complete analysis for ONC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
